

LETTER TO THE EDITOR

Retrospective evaluation of a TEN/SJS series managed with a new treatment protocol

Dear Editor,

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening diseases without standardized treatment. The mortality rate ranges from 20% to 50%, and can reach up to 90%, based on the severity index SCORTEN.¹ Albeit critical, no active systemic therapeutic regimen with unequivocal benefit exists as of yet; most included cyclosporine A (CyA), immunoglobulins (IVIG) or systemic glucocorticosteroids (GCS).² Anti-TNF therapy has been described as beneficial in some reports,^{3–5} and a randomized controlled trial was discontinued prematurely because of death excess in the thalidomide treatment group.⁶ In the EuroSCAR cohort study, administration of IVIG resulted in a mortality rate of 34% (IVIG alone) and 18% (IVIG and corticosteroids).⁷ However, there is no reliable consensus on the benefits or lack of benefit of any systemic treatment or combinations thereof.^{8–10} Here, we report a reduction of patient mortality using a standardized triple therapy (starting 3 mg/kg CyA + 1–2 g IVIG over 3–5 days + 1 mg/kg GCS) along with an early intervention standard intensive care protocol (CPG) (Figure 1). The retrospective analysis included a total of 96 patients, 52 (54.2%) were diagnosed with SJS, 24 (25.0%) had TEN and 20 (20.8%) had SJS/TEN (Table 1). We further report an incidence of 0.36–3.53 per million TEN cases per year in Qatar, the highest reported incidence of TEN worldwide published yet. The most common causative drugs were ibuprofen (17%), Augmentin (14%), paracetamol (14%) and allopurinol (10%). Among all 96 patients, 57 (59.4%) patients had monotherapy or none, 15 (15.6%) had double therapy and 24 (25.0%) patients received triple therapy. SCORTEN was categorized into two groups: 0–2 ($n=76$; 80.9%) and +3 score points ($n=18$; 19.1%). Overall mortality was estimated at 8.4% ($n=8$). The SCORTEN was significantly associated with mortality (Fisher's exact test p -value < 0.001). Simple logistic regression estimated an unadjusted mortality odds ratio of 47.73 (95% CI 5.35–425.93;

p -value < 0.001) with a SCORTEN of 3+ versus 0–2. Although univariable analysis (Fisher's Exact test) did not show that triple therapy together with CPG is associated with reduced mortality (p -value > 0.999), simple logistic regression estimated an unadjusted odds ratio for mortality of 0.99 (95% CI 0.19–5.24; p -value = 0.986) for those with triple therapy and standardized care protocol. Among TEN patients, mortality dropped from 67% (2 deaths/3 patients) in 2018 to 0% (0 death/3 patients) in 2021. Among SJS/TEN patients, mortality dropped from 25% (1 death/4 patients) in 2018 to 0% (0 death/1 patients) in 2021. After introducing triple therapy in 2018, there was a 22% drop in mortality by 2021 overall, specifically a 9%, 67% and 25% drop in mortality among SJS, TEN and SJS/TEN patients, respectively. Next to the drop in mortality, patients showed fewer side effects (e.g. infections). Wounds and pulmonary infections were reported among 56 patients (58.9%), with a similar distribution among SJS, SJS/TEN and TEN (p -value = 0.939). Eye complications were reported in 44 patients, also showing no significant difference between treatment groups (p -value = 0.089). Following the introduction of triple therapy, a decrease in complications was reported, albeit statistically non-significant. This is a new protocol compared to published literature and demonstrates thus far one of the highest reductions in mortality for SJS/TEN in a comparable cohort. Limitations of the study include the open-label and non-randomized nature of the study preventing to unequivocally conclude the triple therapy regimen efficacy in SJS/TEN. Furthermore, despite histopathological confirmation and board-certified dermatologist diagnosis of SJS/TEN, the possibility of misdiagnosis cannot be completely ruled out. Other limitations include the low number of patients and improved supportive care which could contribute to better survival outcomes. In the future, large-scale prospective randomized studies are urgently needed to validate the benefit of the new triple therapy on mortality/morbidity for patients with SJS/TEN.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Authors. *Journal of the European Academy of Dermatology and Venereology* published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Suspected SJS/TEN: Mucocutaneous Responses,		
Names of SJS/TEN Team Members (specialized personnel, chairman, etc.)		
Patient of Dermatology Dept (Outpatients only in Qatar) - Dermatology arranges transfer to Emergency Department	Patient of Dermatology Dept. (Outpatients only in Qatar) - Dermatology arranges transfer to Emergency Department	
Immediate Ambulance transfer to ED: Assessment within first 2 h	Dermatology On-Call Team: Assessment within first 2 h	
Immediate Assessment on Presentation: Admission with one-to-one nurse, continuous monitoring for vitals, isolated room for protective measures, establish IV access, start IV fluids and monitor fluid balance since arrival, identify culprit drug and remove it immediately , document the drug allergy immediately in the system. Fluid Replacement (0.9% Saline or Ringer lactate): 2 ml/kg ideal BW/% BSA epidermal detachment (half 1 st 8 h, half next 16 h)		
Initial investigation: CBC, CMP, CRP, Mg, Phosphate, VBG, Crea, Glucose, Mycoplasma serology, Herpes serology, EBV, CMV, HIV, Chest X-Ray, Swab for (an)aerobe blood culture (bacterial and fungal from 3 different sites of areas of necrolysis/erosions)	Frequency of investigations: Daily SCORTEN documentation, Daily order for urea, glucose, bicarbonate levels, Swabs for Blood culture: every 48 h	
Prognostic Factors Points	SCORTEN	Expected Mortality (%)
Age > 40 years, Neoplasia, Tachycardia > 120 bpm	0-1	3
Initial Detachment > 10%	2	12
Serum Urea > 10 mmol/L	3	35
Serum Bicarbonate < 20 mmol/L	4	58
Blood Glucose > 14 mmol/L	≥5	90
To Be Completed by Dermatology On-Call		
<ol style="list-style-type: none"> 1. Immediate Biopsy 2. Assessment for pain: skin, mucosa, eyes, chest (trachea), esophagus (swallowing). Use validated pain tool 3. Analgesia: e.g. morphine and paracetamol. Daily assessment 4. Insert urinary catheter when BSA > 30% of epidermal necrolysis, and/or if urogenital involvement 5. Skin management, daily inspection and review 6. Wound care: Warm sterile water, saline or an antiseptic such as chlorhexidine (1/5000) 		
Multidisciplinary Team Care (ENT, Ophthalmology, Urology, Gynecology, Pulmonology, GI):		
<ol style="list-style-type: none"> 1. ENT, Ophthalmology & Urology/Gynecology review if local involvement. 2. Admission to MICU if > 10% epidermal loss with any sign of deterioration (tachycardia, tachypnea, drop in oxygen saturation, SCORTEN > 2, fever, sepsis), Fibre-optic bronchoscopy (Hypoxemia) 		
Systemic Treatment (decided by SJS/TEN Dermatology MDT)		
Triple therapy (Cyclosporine, IVIG, and Systemic Corticosteroids)		
(* can add Etanercept if needed)		
<ol style="list-style-type: none"> 1. Dose and duration of Cyclosporine: 3-5 mg/kg/day for 7 days, and then tapered over a further 7 days (CAVE: assess renal impairment) 2. Dose and duration of corticosteroids: 1-1.5 mg/kg (don't exceed 1.5 mg/kg) of prednisolone (OR equivalent IV dexamethasone) for 3 days, taper over next 2 days, then stop (only given at acute phase < 48 h) 3. Dose and duration of IVIG: 1 g/kg/day infusion over 8 hours for 3-5 days (check for renal/liver impairment) 4. *Dose and duration of TNF-α inhibitors (Etanercept): 50 mg of etanercept in a single subcutaneous injection 		
Discharge and Follow-Up: MediAlert Bracelet		

FIGURE 1 Clinical practice guidelines (CPG) for the diagnosis and management of SJS/EN in the State of Qatar. The CPG applies to all adult patients presenting with SJS, TEN or with SJS/TEN. Immediate assessment on presentation includes initial investigation: CBC, CMP, CRP, magnesium, phosphate, VBG, creatinine, glucose, mycoplasma serology, herpes serology, EBV, CMV, HIV, chest x-ray, swab for culture (bacterial and fungal from three different sites of areas of necrolysis/erosions). Triple therapy (cyclosporine, IVIG and systemic corticosteroids): Dose and duration of cyclosporine: 3–5 mg/kg/day for 7 days, and then tapered over a further 7 days (make sure there is no renal impairment). Dose and duration of corticosteroids: 1–1.5 mg/kg (not to be exceeded) of prednisolone (or equivalent IV dexamethasone) for 3 days, tapered in the next 2 days, then stop (only given at acute phase <48 h; pay attention to risk of sepsis). Dose and duration of IVIG: 1 g/kg/day infusion over 8 h for 3–5 days (make sure there is no renal/liver impairment). Dose and duration of TNF-α inhibitors (etanercept): 50 mg of etanercept was administered in a single subcutaneous injection. TNF-α inhibitors were used as monotherapy, second-line therapy or combination therapy.

TABLE 1 Mortality rates of cases of SJS, SJS/TEN and TEN diagnosed from 2015 to 2021.

		Death/case (% mortality)			
		SJS	TEN	SJS/TEN	Combined
Year of onset	2015	0/6; 0%	0/1; 0%	0/2; 0%	0/9; 0%
	2016	0/1; 0%	0/3; 0%	1/4; 25%	1/8; 13%
	2017	0/11; 0%	1/1; 100%	0/2; 0%	1/14; 7%
	2018	1/11; 9%	2/3; 67%	1/4; 25%	4/18; 22%
	2019	0/16; 0%	1/4; 25%	0/1; 0%	1/21; 5%
	2020	0/4; 0%	0/7; 0%	1/6; 17%	1/17; 6%
	2021	0/3; 0%	0/5; 0%	0/1; 0%	0/9; 0%

FUNDING INFORMATION

Supported by MRC Fund #MRC-01-21-763, Hamad Medical Corporation, Qatar (to M.S., J.B. and S.A.K.).

CONFLICT OF INTEREST STATEMENT


M.S. is a consultant for Pfizer, Janssen, Eli-Lilly, Novartis, Abbvie, UCB, Celgene, Galderma, Leo, MenloTx, Sanofi and Regeneron. Grants by Pfizer, Novartis, Leo, Galderma and a speaker for Pfizer, Janssen, Eli-Lilly, Novartis, Abbvie, UCB, Celgene, Galderma, Leo, MenloTx, Sanofi, Union and Regeneron. S.A.K., J.B. and F.J. are investigators in a Novartis-sponsored clinical study. J.B. holds shares of Immatics N.V. and BioNTech. All other authors declare that they do not have any conflict of interest within the scope of the submitted work.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICAL APPROVAL

This study was conducted in accordance with the Declaration of Helsinki and was performed according to national laws and approved by the relevant Human Ethics Review Committee, approval #MRC-01-21-763.

Martin Steinhoff^{1,2,3,4,5,6} 
 Joerg Buddenkotte^{1,2,3}
 Wadha Al-Shafi¹
 Hissa Al-Marri¹
 Fatima Emam¹
 Mariam Iqneibi¹
 Tim Richard Edmund Harris⁷
 Stephen H. Thomas⁷
 Syed Muhammad Asad⁸
 Hanan Al-Maslamani¹
 Febu Elizabeth Joy^{1,3}
 Lubna Therachiyil²
 Anh Jochebeth^{1,2,3}
 Rari Leo^{1,2}
 Shahad M. Younis²
 Laith Jamal Abu Raddad⁴
 Soha Roger Dargham⁴
 Sara Al-Khawaga^{1,2,3,4,8}

¹Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar

²Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar

³Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar

⁴Weill Cornell Medicine-Qatar, Doha, Qatar

⁵College of Medicine, Qatar University, Doha, Qatar

⁶Department of Dermatology, Weill Cornell Medicine, New York City, New York, USA

⁷Emergency Medicine, Hamad Medical Corporation, Doha, Qatar

⁸College of Health and Life Sciences, Hamad Bin Khalifa University-Qatar, Ar-Rayyan, Qatar

Correspondence

Martin Steinhoff and Sara Al-Khawaga, Department of Dermatology and Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Email: msteinhoff@hamad.qa and salkhawaga@hamad.qa

Martin Steinhoff and Joerg Buddenkotte contributed equally as first author.

ORCID

Martin Steinhoff  <https://orcid.org/0000-0002-7090-2187>

REFERENCES

- McCullough M, Burg M, Lin E, Peng D, Garner W. Steven Johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience. *Burns*. 2017;43(1):200–5.
- Creamer D, Walsh SA, Dziejewski P, Exton LS, Lee HY, Dart JKG, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. *J Plast Reconstr Aesthet Surg*. 2016;69(6):e119–e153.
- Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. *J Am Acad Dermatol*. 2014;71(2):278–83.
- Zhang S, Tang S, Li S, Pan Y, Ding Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. *J Dermatol Treat*. 2020;31(1):66–73.
- Cao J, Zhang X, Xing X, Fan J. Biologic TNF-alpha inhibitors for Stevens-Johnson syndrome, toxic epidermal necrolysis, and TEN-SJS overlap: a study-level and patient-level meta-analysis. *Dermatol Ther (Heidelb)*. 2023;13(6):1305–27.

6. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. *Lancet*. 1998;352(9140):1586–9.
7. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. *J Am Acad Dermatol*. 2008;58(1):33–40.
8. Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. *J Invest Dermatol*. 2018;138(11):2315–21.
9. McPherson T, Exton LS, Biswas S, Creamer D, Dziewulski P, Newell L, et al. British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. *Br J Dermatol*. 2019;181(1):37–54.
10. Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health working group. *JAMA Dermatol*. 2017;153(6):587–92.